You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海凱寶(300039.SZ)半年度淨利潤降16.46%至1.53億元
格隆匯 08-21 19:56

格隆匯8月21日丨上海凱寶(300039.SZ)發佈2019年半年度報告,實現營業收入7.88億元,同比下降13.10%;歸屬於上市公司股東的淨利潤1.53億元,同比下降16.46%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤1.45億元,同比下降18.18%;基本每股收益0.1435元。

2019年,隨着國家醫改政策的持續深入推進,醫藥行業不斷強化監管規範,醫保控費、兩票制、仿製藥一致性評價、“4+7”藥品國家集採、DRG和國家重點監控藥品目錄等政策陸續實施,對醫藥行業的市場帶來巨大沖擊。

研發與創新是企業發展戰略的重要組成部分。報告期內,公司研發工作紮實推進,持續加大研發投入力度,有序推進研發項目進程,不斷豐富產品梯隊化建設,同時不斷提高科研隊伍的綜合素質,提升公司科研創新能力。報告期內,公司一方面加強自身產品的研發進度,加快推進主營產品痰熱清的二次開發及系列品種的研發進度,積極推進國家三五重大新藥創制項目體外培育熊膽粉、痰熱清注射液再評價及痰熱清注射液抗耐藥菌等方面的研究。另一方面對外積極考察,圍繞呼吸、心腦血管、消化以及腫瘤等四大領域開展工作,以不斷豐富產品梯隊化建設,逐步完善產品及銷售的協同效應。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account